<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345968</url>
  </required_header>
  <id_info>
    <org_study_id>UKM10_0027</org_study_id>
    <secondary_id>2010-024115-14</secondary_id>
    <secondary_id>05-AnIt-09</secondary_id>
    <nct_id>NCT01345968</nct_id>
  </id_info>
  <brief_title>Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery</brief_title>
  <acronym>PRIVIRON</acronym>
  <official_title>Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients With Orthopedic Surgery and High Risk of Blood Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and efficacy of preoperative
      intravenous ferric carboxymaltose in patients with anemia undergoing hip or knee replacement
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Less patients than expected for inclusion, therefore recruitment is too low
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of RBC units</measure>
    <time_frame>Until postoperative day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion rate</measure>
    <time_frame>Until postoperative day 7</time_frame>
    <description>Number of patients with blood transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of postoperative complications</measure>
    <time_frame>Until postoperative day 7</time_frame>
    <description>Number of postoperative complications from baseline until postoperative day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of postoperative complications</measure>
    <time_frame>Until 6 weeks after surgical intervention</time_frame>
    <description>Number of postoperative complication from baseline until 6 weeks after surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>6 weeks after surgical intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Anemia</condition>
  <condition>Orthopedic Surgery</condition>
  <condition>High Risk of Blood Loss</condition>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject 50 mg/ml</intervention_name>
    <description>iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes</description>
    <arm_group_label>Ferinject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>iv administration of max. 50 ml in 30 minutes</description>
    <arm_group_label>NaCl 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  Patients scheduled to undergo hip or knee replacement

          -  8 g/dl &lt; Hb &lt; 13 g/dl for men and 8 g/dl &lt; Hb &lt; 12 g/dl for women at screening (3-4
             weeks prior to surgery)

          -  anemia

          -  signed written informed consent

        Exclusion Criteria:

          -  immunosuppressive or myelosuppressive therapy

          -  history of thromboembolic events

          -  a concurrent medical condition(s) that would prevent compliance or participation or
             jeopardize the health of the patient

          -  hypersensitivity to any component of the formulation

          -  transfusion within 1 month prior to study inclusion

          -  liver values 3 times higher than normal

          -  active severe infection/inflammation

          -  renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo K Van Aken, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia and Intensiv Care, University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>transfusion</keyword>
  <keyword>intravenous ferric carboxymaltose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

